Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Neurodegener Dis. 2013 Sep 6;13(1):29–37. doi: 10.1159/000351606

Figure 3.

Figure 3

Panels A-C: Mean blood glucose (mg/dL) (± S.E.M.) over time for control and SOD1-G93A mice at the early, middle, and late stages. Male and female mice were combined within groups. Systemic glucose clearance in early, middle, and late stage SOD1-G93A mice did not differ significantly from that of control mice. Panel D: Mean serum insulin (ng/mL) (± S.E.M.) for control and SOD1-G93A mice at the early, middle, and late stages. At each stage, 2-sample t-tests revealed no significant differences in mean serum insulin between control and SOD1-G93A mice. Breaks indicate that across-stage comparisons were not performed.